Congressional opioid efforts targeting Medicare, limits on new prescriptions
Published by McKnight’s Long-Term Care News
A bipartisan group of senators introduced legislation Tuesday that would set a three-day initial prescribing limit on opioids for acute pain and increase recovery services and availability for addicts.
The legislation would change policies and make more funding available through the $6 billion earmarked for opioids and mental health treatment in a two-year budget deal struck last month.
The Senior Care Pharmacy Coalition urged lawmakers to stick with the precedent established in 2016 and exempt long-term care facilities from the proposed three-day limit. The current version only includes an exception for hospice care.
“Patients in long-term care settings are at very low risk for opioid abuse, and those prescribed opioids suffer intense and severe pain which mean that some dispensing limits inadvertently threaten effective pain management,” said Alan G. Rosenbloom, SCPC president and CEO.
One in three participants in Medicare’s prescription drug program received a prescription for opioids in 2016, according to the Office of Inspector General. Across the country, overdose deaths increased nearly 28% from 2015 to 2016, according to the latest data from the Centers for Disease Control and Prevention.
The House Energy and Commerce Committee held its first of three hearings Wednesday to discuss legislation, while the Ways and Means Committee has already made it clear Medicare’s handling of opioids will be in its sights.
The committee has asked insurers, benefit managers, providers and prescribers to submit information by March 15 that addresses how Medicare can help stem the epidemic. Members specifically want information on overprescribing, data tracking, treatment, communication and education, The Hill reported.
Senior Care Pharmacy Coalition Applauds Chairman Comer and House Oversight Committee for Shedding Light on Harmful PBM Practices, Encourages Congress to Advance PBM Reform Legislation Heard Today in House Energy and Commerce Committee Health Subcommittee
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, released a statement today regarding the House Oversight Committee’s hearing on pharmacy benefit managers.
Stuck in the middle, LTC pharmacies could be dangerously squeezed by drug price negotiations
Any lower drug prices that result from White House efforts to negotiate on behalf of Medicare beneficiaries may lead to short-term gains for nursing homes, but there also could be a steep price to pay in the long-term, experts warned this week. The Centers for Medicare & Medicaid Services on Tuesday announced the first 10 drugs covered by Medicare Part D that will be included in negotiations running through 2024. They are all commonly prescribed drugs that treat conditions ranging from diabetes to arthritis and heart failure.
Biden’s Plans to Reduce Cost of Medicare Drugs To Send Ripple Effects Through Nursing Home Industry
Following the Biden Administration’s bid this week to reduce the price of certain drugs – many of which are commonly used in nursing homes – experts are cautioning that the changes may negatively impact the bottomline of organizations in the sector. As Medicare Part D price negotiations for these drugs come into focus this week, the Senior Care Pharmacy Coalition (SCPC), for one, is warning that changes to Part D might cause “collateral damage” to long-term care pharmacies, the patients they serve and operator partners.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.